

Substernal Implantable Cardioverter-Defibrillator System

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

[Effective Date](#) 4/2014
[Next Review Date](#) 7/15/2024
[Coverage Policy](#) Surgical 130
[Version](#) 2

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Purpose:

This policy addresses the Substernal Implantable Cardioverter-Defibrillator System.

Description & Definitions:

Substernal Implantable Cardioverter-Defibrillator System is an electronic device with a generator which is implanted under the left side rib cage with lead wires that reside under the sternum instead of through the veins, and closer to the heart. The device monitors abnormal heart rhythms; when detected a shock is sent to the heart to restore a normal rhythm, it also has the ability to deliver anti-tachycardia pacing (ATP) and bradycardia pacing or resynchronization therapy.

Criteria:

Substernal Implantable Cardioverter-Defibrillator System is considered **not medically necessary** for any indications.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
0571T	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed
0572T	Insertion of substernal implantable defibrillator electrode

0573T	Removal of substernal implantable defibrillator electrode
0574T	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter
0577T	Electrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results
0580T	Removal of substernal implantable defibrillator pulse generator only
0614T	Removal and replacement of substernal implantable defibrillator pulse generator

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2022: July
- 2021: July
- 2019: December
- 2016: January, April
- 2015: July

Reviewed Dates:

- 2023: July
- 2021: November
- 2020: November
- 2018: August
- 2017: December
- 2016: March
- 2015: March

Effective Date:

- April 2014

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Code of Federal Regulations. § 4.104 Schedule of ratings—cardiovascular system. Title 38. Chapter 1. Part 4. Subpart B. The Cardiovascular System. Diseases of the Heart. (6.30.2023). Retrieved 7.10.2023. <https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104>

(2023). US Food and Drug Administration. Implantable Cardioverter Defibrillator (Non-Crt). Data base. (7.10.2023). Retrieved 7.10.2023. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=LWS>

(2023). Hayes. A symplr company. Emerging Technology Report. Extravascular Implantable Cardioverter Defibrillator. (12.12.2022). Retrieved 7.10.2023. <https://evidence.hayesinc.com/report/pg.evicd>

(2023). MCG, Informed Care Strategies. Electrophysiologic Study and Implantable Cardioverter-Defibrillator (ICD) Insertion. ORG: M-157 (AC). (9.1.2022). Retrieved 7.10.23. <https://careweb.careguidelines.com/ed26/index.html>

(2023). Centers for Medicare and Medicaid Services. CMS.gov. Billing and Coding: Implantable Automatic Defibrillators. A57994. (1.1.2021). Retrieved 7.10.23. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57994&ver=4&keyword=Implantable%20Automatic%20Defibrillators&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

(2023). Cardinal Care. Virginia's Medicaid Program. Procedure Fee Files and CPT Codes. (2023). Retrieved 7.10.2023. <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

(2023). Carel Medical Management Clinical Appropriateness Guideline. Implantable Cardioverter Defibrillators 2021-11-07. Retrieved 7.10.2023. <https://guidelines.carelonmedicalbenefitsmanagement.com/implantable-cardioverter-defibrillators-2021-11-07/>

(2023). American College of Cardiology. Search for Substernal implantable cardioverter-defibrillator. (2023). Retrieved 7.10.23. <https://www.acc.org/Guidelines#/results/substernal%20implantable%20cardioverter-defibrillator>

(2023). Molnár, L., Crozier, I., Haqqani, H., O'Donnell, D., Kotschet, E., Alison, J., Thompson, A. E., Bhatia, V. A., Papp, R., Zima, E., Jermendy, Á., Apor, A., & Merkely, B. (2022). The extravascular implantable cardioverter-defibrillator: characterization of anatomical parameters impacting substernal implantation and defibrillation efficacy. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*, 24(5), 762–773. Retrieved 7.10.23. PubMed. National Library of Medicine. <https://doi.org/10.1093/europace/euab243>.

(2023) United link takes you to EviCore. Clinical Guidelines. Cardiac Implantable Devices. (CID). Version 1.1.2023. (2.15.23). Retrieved 7.11.23. https://www.evicore.com/-/media/files/evicore/provider/network-standard/evicore-cardiac-implantable-devices-cid-guidelines_v102023_eff02152023_pub11212022.pdf

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice.

Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to “correct or ameliorate” (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

Substernal Implantable Cardioverter-Defibrillator System, SHP Surgical 130, extracardiac ICD, EV ICD